Suvorexant in Insomnia Co-morbid With Fibromyalgia
A Double-blind, Crossover, Study to Compare the Hypnotic, Daytime Sleepiness/Fatigue, and Pain Effects of Nighttime Administration of Suvorexant 20 mg Versus Placebo in Patients With Fibromyalgia and Comorbid Insomnia
Sponsor: Henry Ford Health System
Terminated
reduced ability to recruit sufficient number of patients
Other terminated trials from Henry Ford Health System
Other Fibromyalgia trials with similar outcome
This PHASE4 trial investigates Fibromyalgia and Insomnia and is currently terminated or withdrawn. Henry Ford Health System leads this study, which shows 13 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE4
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE4
▶ Show 8 earlier versions
-
Sep 2021 — Dec 2021 [monthly]
Terminated PHASE4
-
Jun 2021 — Sep 2021 [monthly]
Terminated PHASE4
-
May 2021 — Jun 2021 [monthly]
Terminated PHASE4
-
Jan 2021 — May 2021 [monthly]
Terminated PHASE4
-
Sep 2018 — Jan 2021 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Henry Ford Health System
For direct contact, visit the study record on ClinicalTrials.gov .